Out @NatureAging 🚨 We propose a cost-effective 2-step workflow to determine Aβ-status in memory clinics: 🩸 pTau217-based risk stratification (step 1; >90% accuracy) followed by confirmatory CSF/PET (step 2) only in uncertain pts (~30%). @OskarHansson9 nature.com/articles/s4358…
We 1st tested the workflow in BioFINDER-1 and -2 cohorts w/ Lilly p-tau217 assay, showing in TRIAD that the workflow generalizes to different assays Special thanks to @OskarHansson9, Kaj Blennow & @biofinder_study team for all the support! And to @pedrorosaneto & @Imaging_AD!
@wagnersbrum @NatureAging @OskarHansson9 @NicholasAshton @erzimmer @JosephTherr @andrealessa @CecileTss @SebastianPalmqv @EStomrud @pedrorosaneto @biofinder_study Great work, Wagner and team! These are very useful concepts.
@wagnersbrum @NatureAging @OskarHansson9 @NicholasAshton @erzimmer @JosephTherr @andrealessa @CecileTss @SebastianPalmqv @EStomrud @pedrorosaneto @biofinder_study Congratulations @wagnersbrum and all the team! 👏🏿👏🏽👏🏻
@wagnersbrum @NatureAging @OskarHansson9 @NicholasAshton @erzimmer @JosephTherr @andrealessa @CecileTss @SebastianPalmqv @EStomrud @pedrorosaneto @biofinder_study Congratulations Wagner on such an interesting and important work 👏🏻👏🏻👏🏻
@wagnersbrum @NatureAging @OskarHansson9 @NicholasAshton @erzimmer @JosephTherr @andrealessa @CecileTss @SebastianPalmqv @EStomrud @pedrorosaneto @biofinder_study Is there a proposal for the healthy non-symptomatic, perhaps SCD?